ArticleTranslational cancer research2025
Systemic immune response induced by radiofrequency ablation versus microwave ablation at varying powers in murine models of hepatocellular carcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives.Immunotherapy · 2026Review
- The Emerging Role of Ablation in the Treatment of Primary and Metastatic Cancer of the Liver.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thermal ablation for orthotopic tumors can activate the immune system, eliciting tumor-specific immune responses. With the recognition of the immune system's role in cancer outcomes and the demand for effective immunotherapies, there is a clinical need to optimize ablation techniques to enhance anti-tumor immunity. This study evaluates the effects of microwave ablation (MWA) and radiofrequency ablation (RFA) at varying powers and durations on systemic T cell profiles and cytokine levels. Methods: Subcutaneous murine hepatocellular carcinoma (HCC) models were established. A total of 50 mice were randomly allocated into five groups, with 10 mice in each group: high-power MWA (10 W, 30 s), low-power MWA (5 W, 60 s), high-power RFA (10 W, 30 s), low-power RFA (5 W, 60 s), and untreated control group. Peripheral CD3 Results: High-power (10 W) ablation boosted adaptive immunity on day 14 post-procedure, manifested as significantly elevated CD3 Conclusions: High-power MWA and RFA can notably activate systemic immunity and enhance Th1 response. These findings underscore the potential of optimizing ablation parameters (such as higher power and shorter duration) to amplify anti-tumor immunity, bridging local tumor control with systemic immune activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.